Diligence memo · auto-generated · as of July 2, 2026
MDI Therapeutics, Inc.
MDI Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
MDI Therapeutics, Inc. operates in Biotechnology, based in NOVI.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
MDI Therapeutics, Inc. has raised $3.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.7M on 2022-02-28.
Most recent recorded round closed around 2022-02-28.
Valuation (modeled)modeled
Provath models MDI Therapeutics, Inc. at approximately $30M (range $1.2M–$149M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.10× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 44 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 35% of Biotechnology peers (4293 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.